Notable Reporting: Daxor Corp (NYSEMKT:DXR) Q2 2016 Sentiment Report

November 22, 2016 - By Hazel Jackson   ·   0 Comments

Notable Reporting: Daxor Corp (NYSEMKT:DXR)  Q2 2016 Sentiment Report

Sentiment for Daxor Corp (NYSEMKT:DXR)

Daxor Corp (NYSEMKT:DXR) institutional sentiment is 1 in 2016 Q2. Its the same as in 2016Q1. The ratio has no change, as only 3 institutional investors increased and started new stock positions, while 3 sold and trimmed stock positions in Daxor Corp. The institutional investors in our partner’s database now hold: 151,568 shares, up from 151,208 shares in 2016Q1. Also, the number of institutional investors holding Daxor Corp in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 1 Increased: 1 New Position: 2.

Daxor Corporation is an investment company with medical instrumentation and biotechnology operations. The company has a market cap of $31.73 million. The Firm engages in the short selling of stock. It currently has negative earnings. The Firm maintains a diversified securities portfolio, which consists primarily of the common and preferred stocks of electric utility companies.

The stock decreased 3.72% or $0.34 on November 21, hitting $8.71. Daxor Corporation (NYSEMKT:DXR) has risen 8.88% since April 20, 2016 and is uptrending. It has outperformed by 4.32% the S&P500.

According to Zacks Investment Research, “Daxor Corporation is a medical device manufacturing corporation with additional biotech services.”

Blackrock Fund Advisors holds 0% of its portfolio in Daxor Corporation for 131 shares. California Public Employees Retirement System owns 13,700 shares or 0% of their US portfolio. Moreover, Deutsche Bank Ag has 0% invested in the company for 54 shares. The New York-based Renaissance Technologies Llc has invested 0% in the stock. Tower Research Capital Llc (Trc), a New York-based fund reported 1,290 shares.#img1#

DXR Company Profile

Daxor Corporation, incorporated on May 5, 1971, is an investment firm with medical instrumentation and biotechnology operations. The Firm engages in the short selling of stock. The Firm maintains a diversified securities portfolio, which consists primarily of the common and preferred stocks of electric utility companies. The Firm has approximately 70 Blood Volume Analyzers (BVA)-100. It also sells Volumex Kits. The Company’s IDANT division provides semen banking services, which include anonymous donor semen and semen storage; autologous blood storage; andrology services, which include semen analysis and sperm washing, and general lab testing.

More important recent Daxor Corporation (NYSEMKT:DXR) news were published by: Marketwired.com which released: “Daxor Corporation Announces Hiring of Chief Financial Officer” on June 17, 2016, also Marketwired.com published article titled: “Daxor Corporation Announces Filing of Form N-CSR for December 31, 2014”, Nypost.com published: “Sperm bank accused of discarding hazardous materials” on July 17, 2015. More interesting news about Daxor Corporation (NYSEMKT:DXR) was released by: Nasdaq.com and their article: “Weekly 3-Year Low Stocks: PBR, NJ, DWA, DXR” with publication date: February 11, 2013.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Hazel Jackson


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>